Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of Dec 31, 2026 to Aug 28, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 3 of 4 entries
  2. Primary completion date: Aug 9, 2025 to Aug 9, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v16
  3. Primary completion date: Apr 9, 2024 to Aug 9, 2025v15
  4. Primary completion date changed from estimate of Dec 31, 2024 to Apr 9, 2024
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    v14
  5. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v13
Show 11 earlier versionsHide 11 earlier versions
  1. Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 102 to confirmed 36
    • Site details revised at 2 of 2 sites
    v12
  2. Primary and study completion dates: Dec 31, 2021 to Dec 31, 2022v11
  3. Eligibility criteria expanded, about 40 wordsv10
  4. Lead sponsor: Kami Maddocks to David Bond, MD
    • Primary and study completion dates: Dec 31, 2020 to Dec 31, 2021
    • Site contacts updated at 1 of 2 sites
    v9
  5. Primary and study completion dates: Apr 30, 2020 to Dec 31, 2020v8
  6. Study sites: 1 to 2v7
  7. Re-verified, no change to tracked fieldsv6
  8. Trial status: Suspended to Recruiting
    • Site details revised
    v5
  9. Trial status: Recruiting to Suspended Sponsor's reason: partial clinical hold per FDA
    • Site details revised
    v4
  10. Collaborator revisedv3
  11. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Apr 2020 to Apr 30, 2020
    • Study completion date: Apr 30, 2020
    • Start date: Feb 2017 to Feb 14, 2017
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
David Bond, MD
3 trials monitored
See all monitored trials
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
DLBCL
706 trials monitored
See 46 trials at risk
Follicular Lymphoma
347 trials monitored
See 28 trials at risk
and 1 more disease
This I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and lenalidomide may work better in treating patients with non-Hodgkin or Hodgkin lymphoma.
Trial Details
NCT Number NCT03015896
Lead Sponsor David Bond, MD
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma +7 more
Related terms Burkitt Lymphoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Waldenstrom Macroglobulinemia
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov